Drugs / Belcesiran
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04174118 | Oct 2019 → Jul 2021 | alpha 1-antitrypsin deficiency | Dicerna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05146882 | Dec 2021 → May 2022 | alpha 1-antitrypsin deficiency | Dicerna Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04764448 | Feb 2021 → Dec 2023 | alpha 1-antitrypsin deficiency | Dicerna Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Belcesiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04764448 ↗ |
| Known as | DCR-A1AT | “This is a research study to test an experimental study drug (belcesiran, also known as DCR-A1AT).” NCT04174118 ↗ |
| Known as | DCR-S1459 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650380 ↗ |
| Route | Subcutaneous | “belcesiran will be administered subcutaneously (SC) at dose levels planned.” NCT04174118 ↗ |